12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bosulif bosutinib regulatory update

The U.K.'s NICE issued a final guidance recommending against the use of Bosulif bosutinib from Pfizer to treat previously treated chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) - its approved indication. The final guidance is in line with a final appraisal determination issued in October (see BioCentury, July 22)....

Read the full 250 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >